Edition:
United States

Aveo Pharmaceuticals Inc (AVEO.OQ)

AVEO.OQ on NASDAQ Stock Exchange Capital Market

3.00USD
16 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.00
Open
$2.98
Day's High
$3.05
Day's Low
$2.92
Volume
574,940
Avg. Vol
324,007
52-wk High
$4.24
52-wk Low
$0.50

Latest Key Developments (Source: Significant Developments)

AVEO Says EUSA Pharma Granted Positive NICE Recommendation For Fotivda
Monday, 12 Feb 2018 07:02am EST 

Feb 12 (Reuters) - Aveo Pharmaceuticals Inc ::AVEO ANNOUNCES EUSA PHARMA GRANTED POSITIVE NICE RECOMMENDATION FOR FOTIVDA® (TIVOZANIB) AS FIRST LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA.AVEO PHARMACEUTICALS INC - ‍RECOMMENDATION TRIGGERS $2MLN MILESTONE PAYMENT FROM EUSA TO AVEO​.  Full Article

Aveo Pharma Entered Into Binding MoU With Class Representatives Regarding Settlement Of A 2013 Class Action Lawsuit
Tuesday, 26 Dec 2017 05:42pm EST 

Dec 26 (Reuters) - Aveo Pharmaceuticals Inc ::AVEO PHARMACEUTICALS - ENTERED INTO BINDING MOU WITH CLASS REPRESENTATIVES BOB LEVINE & WILLIAM WINDHAM REGARDING SETTLEMENT OF A 2013 CLASS ACTION LAWSUIT.AVEO- UNDER MOU, AGREED FOR PLAINTIFFS TO CAUSE SOME OF CO'S, INDIVIDUAL DEFENDENTS' INSURANCE CARRIERS TO PROVIDE THE CLASS WITH $15 MILLION CASH PAYMENT.AVEO PHARMACEUTICALS SAYS ADDITIONALLY, CO AGREED TO ISSUE TO THE CLASS WARRANTS FOR PURCHASE OF 2 MILLION SHARES OF AVEO COMMON STOCK - SEC FILING.AVEO PHARMACEUTICALS - IN CONSIDERATION OF SETTLEMENT PAYMENT, PLAINTIFFS AGREED THAT SETTLEMENT WILL INCLUDE DISMISSAL OF CLASS ACTION WITH PREJUDICE.AVEO PHARMA - CONSIDERING SETTLEMENT PAYMENT, PLAINTIFFS AGREED SETTLEMENT WILL INCLUDE RELEASE OF ALL CLAIMS AGAINST CO, INDIVIDUAL DEFENDANTS BY THE CLASS.  Full Article

Aveo Pharmaceuticals Files For Mixed Shelf Of Upto $200 Mln
Thursday, 30 Nov 2017 05:39pm EST 

Nov 30 (Reuters) - Aveo Pharmaceuticals Inc ::AVEO PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.  Full Article

AVEO PHARMACEUTICALS REPORTS Q3 LOSS PER SHARE $0.22
Tuesday, 7 Nov 2017 07:00am EST 

Nov 7 (Reuters) - Aveo Pharmaceuticals Inc :AVEO REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE $0.22.‍BELIEVE THAT OUR $37.4 MILLION IN CASH RESOURCES WOULD ALLOW US TO FUND OUR PLANNED OPERATIONS INTO Q4 OF 2018​.  Full Article

AVEO Oncology and EUSA Pharma announce TiNivo combination study opt-in
Wednesday, 20 Sep 2017 07:10am EDT 

Sept 20 (Reuters) - Aveo Pharmaceuticals Inc :Aveo Pharmaceuticals Inc - ‍EUSA Pharma has agreed to pay AVEO up to $388 million in future milestone payments and research and development funding​.Aveo - ‍under terms of agreement, EUSA may utilize data from study for regulatory/commercial purposes in exchange for research and development funding payment of $2.0 million​.Aveo Pharmaceuticals Inc - ‍EUSA Pharma agreed to pay co milestone payments under terms of agreement from Dec 2015 ​.  Full Article

Aveo Oncology announces Fotivda approved in the EU for the treatment of advanced renal cell carcinoma
Monday, 28 Aug 2017 06:17am EDT 

Aug 28 (Reuters) - Aveo Pharmaceuticals Inc :Aveo Oncology announces Fotivda® (tivozanib) approved in the European Union for the treatment of advanced renal cell carcinoma.Aveo Oncology says EC has approved fotivdafor treatment of adult patients with advanced renal cell carcinoma in European Union plus Norway and Iceland.  Full Article

Aveo Pharmaceuticals Inc Q2 loss per share $0.30
Wednesday, 9 Aug 2017 07:00am EDT 

Aug 9 (Reuters) - Aveo Pharmaceuticals Inc ::Aveo reports second quarter 2017 financial results and provides business update.Q2 loss per share $0.30.Aveo pharmaceuticals inc - ‍believe that our $40.1 million in cash resources would allow us to fund our planned operations into q4 of 2018​.  Full Article

Aveo Oncology gets $14 mln from Hercules Credit Facility and at-the-market stock offerings
Tuesday, 27 Jun 2017 09:06am EDT 

June 27 (Reuters) - Aveo Pharmaceuticals Inc :Aveo Oncology announces $14m in aggregate gross proceeds from Hercules Credit Facility and at-the-market stock offerings.Aveo Pharmaceuticals Inc - intends to draw down an additional $5 million in funding from Hercules.Aveo Pharmaceuticals Inc - will defer commencement of principal payments on its aggregate loan balance by six months from July 1, 2017 until January 1, 2018..  Full Article

Aveo Oncology announces phase 1/2 tinivo trial
Thursday, 8 Jun 2017 07:00am EDT 

June 8 (Reuters) - Aveo Pharmaceuticals Inc ::Aveo Oncology announces phase 1/2 tinivo trial of tivozanib and opdivo® (nivolumab) in RCC advances to phase 2.Aveo Pharmaceuticals - "Registration strategy for single agent tivozanib reaches key inflection points, with European regulatory decision expected in near-term".Aveo - if registration strategy for single agent tivozanib reaches key inflection points, readout of us registration-directed tivo-3 study expected in Q1 of 2018.  Full Article

Aveo appoints Matthew Dallas chief financial officer
Tuesday, 16 May 2017 07:00am EDT 

May 16 (Reuters) - Aveo Pharmaceuticals Inc -:Aveo announces appointment of Matthew Dallas as chief financial officer.Aveo Pharmaceuticals Inc - Dallas succeeds Keith Ehrlich, whose retirement from company was previously announced.Aveo Pharmaceuticals Inc - appointment of Matthew Dallas as chief financial officer, effective June 1, 2017.  Full Article

BRIEF-Aveo Pharmaceuticals ‍Entered Into Sales Agreement With Leerink Partners

* AVEO PHARMACEUTICALS SAYS ‍ENTERED INTO A SALES AGREEMENT WITH LEERINK PARTNERS - SEC FILING